Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor

New England Journal of Medicine

Volumn 373, Issue 5, 2015, Pages 428-437

  Tap, William D ^a,b   Wainberg, Zev A ^c   Anthony, Stephen P ^f   Ibrahim, Prabha N ^d   Zhang, Chao ^d   Healey, John H ^a   Chmielowski, Bartosz ^c   Staddon, Arthur P ^g   Lee Cohn, Allen ^h   Shapiro, Geoffrey I ⁱ   Keedy, Vicki L ^k   Singh, Arun S ^c   Puzanov, Igor ^k   Kwak, Eunice L ^j   Wagner, Andrew J ⁱ   Von Hoff, Daniel D ^l   Weiss, Glen J ^l   Ramanathan, Ramesh K ^l   Zhang, Jiazhong ^d   Habets, Gaston ^d   Zhang, Ying ^d   Burton, Elizabeth A ^d   Visor, Gary ^d   Sanftner, Laura ^d   Severson, Paul ^d   Nguyen, Hoa ^d   Kim, Marie J ^d   Marimuthu, Adhirai ^d   Tsang, Garson ^d   Shellooe, Rafe ^d   Gee, Carolyn ^d   West, Brian L ^d   Hirth, Peter ^d   Nolop, Keith ^d   Van De Rijn, Matt ^e   Hsu, Henry H ^d   Peterfy, Charles ^m   Lin, Paul S ^d   Tong Starksen, Sandra ^d   Bollag, Gideon ^d   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PLEXXIKON INC   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Evergreen Hematology and Oncology   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h ROCKY MOUNTAIN CANCER CENTERS   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

^k VANDERBILT UNIVERSITY   (United States)

^l TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^m Spire Sciences Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 [[5 CHLORO 1H PYRROLO(2,3 B)PYRIDIN 3 YL]METHYL] N [[6 (TRIFLUOROMETHYL)PYRIDIN 3 YL]METHYL]PYRIDIN 2 AMINE; ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; COLONY STIMULATING FACTOR 1 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; UNCLASSIFIED DRUG; 5-((5-CHLORO-1H-PYRROLO(2,3-B)PYRIDIN-3-YL)METHYL)-N-((6-(TRIFLUOROMETHYL)PYRIDIN-3-YL)METHYL)PYRIDIN-2-AMINE; AMINOPYRIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADENOSQUAMOUS CARCINOMA; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CONTROL; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG WITHDRAWAL; DYSGEUSIA; FAINTNESS; FATIGUE; GIANT CELL TUMOR; HAIR COLOR; HAND PAIN; HUMAN; HUMAN TISSUE; HYPONATREMIA; INTERNATIONAL NORMALIZED RATIO; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; PERIORBITAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SALIVARY GLAND CARCINOMA; SIDE EFFECT; SOLID TUMOR; STRUCTURE ANALYSIS; TENOSYNOVIAL GIANT CELL TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TUMOR REGRESSION; TUMOR VOLUME; X RAY CRYSTALLOGRAPHY; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DOSE RESPONSE; DRUG DEVELOPMENT; FEMALE; GIANT CELL TUMORS; MALE; METABOLISM; PATHOLOGY; SOFT TISSUE NEOPLASMS; TENDON;

ADULT; AGED; AMINOPYRIDINES; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; FEMALE; GIANT CELL TUMORS; HUMANS; MALE; MIDDLE AGED; PYRROLES; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; SOFT TISSUE NEOPLASMS; TENDONS; TUMOR BURDEN;

EID: 84938369565     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1411366     Document Type: Article

References (23)

1. Rubin BP. Tenosynovial giant cell tumor and pigmented villonodular synovitis: a proposal for unification of these clinically distinct but histologically and genetically identical lesions. Skeletal Radiol 2007;36:267-8.
2. Martin RC II, Osborne DL, Edwards MJ, Wrightson W, McMasters KM. Giant cell tumor of tendon sheath, tenosynovial giant cell tumor, and pigmented villonodular synovitis: defining the presentation, surgical therapy and recurrence. Oncol Rep 2000;7:413-9.
3. Ravi V, Wang WL, Lewis VO. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis. Curr Opin Oncol 2011;23:361-6.
4. Verspoor FG, van der Geest IC, Vegt E, Veth RP, van der Graaf WT, Schreuder HW. Pigmented villonodular synovitis: current concepts about diagnosis and management. Future Oncol 2013;9:1515-31.
5. Molena B, Sfriso P, Oliviero F, et al. Synovial colony-stimulating factor-1 mRNA expression in diffuse pigmented villonodular synovitis. Clin Exp Rheumatol 2011;29:547-50.
6. West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giantcell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A 2006;103:690-5.
7. Cupp JS, Miller MA, Montgomery KD, et al. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Am J Surg Pathol 2007;31:970-6.
8. Walter M, Lucet IS, Patel O, et al. The 2.7 A crystal structure of the autoinhibited human c-Fms kinase domain. J Mol Biol 2007;367:839-47.
9. DeNardo DG, Brennan DJ, Rexhepaj E, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011;1:54-67.
10. Coniglio SJ, Eugenin E, Dobrenis K, et al. Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol Med 2012;18:519-27.
11. Xu J, Escamilla J, Mok S, et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res 2013;73:2782-94.
12. Prada CE, Jousma E, Rizvi TA, et al. Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neuropathol 2013;125:159-68.
13. Mitchem JB, Brennan DJ, Knolhoff BL, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res 2013;73:1128-41.
14. Patwardhan PP, Surriga O, Beckman MJ, et al. Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs. Clin Cancer Res 2014;20:3146-58.
15. Zhang C, Ibrahim PN, Zhang J, et al. Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor. Proc Natl Acad Sci U S A 2013;110:5689-94.
16. Østergaard M, Peterfy C, Conaghan P, et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies: core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol 2003;30:1385-6.
17. Peterfy CG, Guermazi A, Zaim S, et al. Whole-Organ Magnetic Resonance Imaging Score (WORMS) of the knee in osteoarthritis. Osteoarthritis Cartilage 2004;12:177-90.
18. Cassier PA, Gelderblom H, Stacchiotti S, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer 2012;118:1649-55.
19. Radi ZA, Koza-Taylor PH, Bell RR, et al. Increased serum enzyme levels associated with Kupffer cell reduction with no signs of hepatic or skeletal muscle injury. Am J Pathol 2011;179:240-7.
20. Amber IB, Clark BJ, Greene GS. Pigmented villonodular synovitis: dedicated PET imaging findings. BMJ Case Rep 2013;2013:bcr2013009401.
21. McTigue M, Murray BW, Chen JH, Deng YL, Solowiej J, Kania RS. Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. Proc Natl Acad Sci U S A 2012;109:18281-9.
22. Wang X, Kim J. Conformation-specific effects of Raf kinase inhibitors. J Med Chem 2012;55:7332-41.
23. Ries CH, Cannarile MA, Hoves S, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 2014;25:846-59.